<DOC>
	<DOCNO>NCT00166530</DOCNO>
	<brief_summary>In patient coronary artery disease LDL-C level 2.5 mmol/L 5.0 mmol/L stable ( &gt; 4 week ) statin start dose ( simvastatin 20 mg atorvastatin 10 mg ) , investigate LCL-C lower efficacy double statin dose ( 40 mg simvastatin 20 mg atorvastatin ) versus combination tablet ezetimibe 10 mg plus simvastatin 20 mg daily 12 week . It postulate patient reach LDL-C treatment goal combination tablet compare double start dose . Furthermore , effect treatment regimens lipid parameter , safety LDL-subfractions measure .</brief_summary>
	<brief_title>EASEGO Study : Doubling Atorvastatin/Simvastatin INEGY Patients With Hypercholesterolemia Coronary Artery Disease ( CAD ) ( 0653A-089 )</brief_title>
	<detailed_description>Patients simvastatin 20 mg atorvastatin 10 mg randomize ( 1 ) double statin dose ( 40 mg simvastatin 20 mg atorvastatin ) ( 2 ) switch combination tablet ezetimibe 10 mg plus simvastatin 20 mg daily 12 week .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Ezetimibe , Simvastatin Drug Combination</mesh_term>
	<criteria>Patient male female 18 year age . Patient stable daily statin start dose past 4 week either : atorvastatin 10 mg ; simvastatin 20 mg lipid value statin monotherapy treatment : LDLC level &gt; 2.5 mmol/L * 5.0 mmol/L , triglycerides &lt; 4.0 mmol/L total cholesterol &lt; 7.0 mmol/L . Patient establish coronary artery disease stable angina ; history myocardial infarction ; history percutaneous coronary intervention ( PTCA without stent placement ) ; coronary stenosis angiography ; history unstable angina nonQ wave myocardial infarction ; history coronary artery bypass graft surgery ( CABG ) ; positive MIBI scan . Patients stable medical condition . Patients cholesterol lower medication regime change previous 4 week . Patients treat investigational drug within 3 month Visit 1 . Patients pregnant lactate . Any condition situation , opinion investigator , might pose risk patient interfere participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>